27th March 2019
EIT Health has recently been involved in a seed collaboration project with Space Application Services.
The EIT Health Community has now been introduced to the new opportunities provided with microgravity in the health industry. Microgravity helps in analysing proteins and large molecules, advancing nanofluidics and improved drug delivery systems, among other applications.
EIT Health has been involved in the project of potential usage of microgravity in the healthcare industry. It applies to biotechnologies, life sciences, physics, as well as medicine. For instance, in life sciences, microgravity can increase virulence and accelerate cell growth.
What’s more, along with influencing biomedical phenomena, spaceflight also can advance nanofluidics. Gravity-dependent forces drive most fluid movement on Earth.
Spaceflight provides a unique environment for studying the nuanced and complex underlying factors associated with biomedical devices that involve fluids, especially at the nanoscale. Microgravity can be used to improve drug delivery systems, healthcare diagnostic tools and other biotechnologies.
Europe is a world leader in Low Earth Orbit (LOE) science and technology research and development. The use of LEO and microgravity provides a strategic business tool, along with R&D advantages, and industrial process optimization. It is a scientific tool as regards microgravity and radiation research, and provides opportunities for in-orbit demonstration and validation (IOV/IOD).
The project is led by Space Application Systems, a Belgian space-oriented company with international offices, that develops innovative systems for different industries, including healthcare.
You can learn more about potential usage of microgravity in science and in healthcare – please contact he EIT Health InnoStars Innovation Manager Mikołaj Gurdała: firstname.lastname@example.org
Four exciting companies receive expert mentoring
EIT Health helps promising firms commercialise
Supported start-up launches AI platform with Roche
Helping cancer patients with AI
EIT Health supported start-up Unhindr awarded £500,000
Unhindr has won funding to scale AI prosthetic device